Explore Business Standard
Sex education should be provided to children from a younger age, and not Class IX onwards, the Supreme Court has said. A bench of Justices Sanjay Kumar and Alok Aradhe said sex education should be part of the curriculum in higher secondary schools so that young adolescents are made aware of the hormonal changes that come with puberty. "We are of the opinion that sex education should be provided to children from a younger age and not Class IX onwards. It is for the authorities concerned to apply their mind and take corrective measures, so that children are informed of the changes that happen after puberty, and the care and cautions to be taken in relation thereto," the bench said. The top court made the observations while granting bail to a 15-year-old boy accused of offences under sections 376 (rape) and 506 (criminal intimidation) of the IPC, and Section 6 (aggravated penetrative sexual assault) of the Protection of Children from Sexual Offences (POCSO) Act. The apex court earlier
Aurobindo Pharma on Tuesday said it will manufacture and supply the long-acting injectable HIV treatment cabotegravir across 133 countries. The Hyderabad-based drugmaker has been selected as one of the generic manufacturers under the expanded voluntary licensing agreement between the Medicines Patent Pool (MPP) and ViiV Healthcare, the company said in a statement. The agreement allows Aurobindo to manufacture and supply the long-acting injectable HIV treatment across 133 countries, including several low and middle-income markets, it added. This update now includes long-acting cabotegravir (CAB LA) for HIV treatment, in addition to its earlier use for prevention only. The treatment offers an alternative to daily pills, allowing patients to receive just one injection every one or two months. "We are privileged to be part of the sub-license expansion from MPP and ViiV to develop, manufacture, and distribute generic CAB LA in select markets for the treatment of HIV-1, in addition to t
Just a week had remained before scientists in South Africa were to begin clinical trials of an HIV vaccine, and hopes were high for another step toward limiting one of history's deadliest pandemics. Then the email arrived. Stop all work, it said. The United States under the Trump administration was withdrawing all its funding. The news devastated the researchers, who live and work in a region where more people live with HIV than anywhere else in the world. Their research project, called BRILLIANT, was meant to be the latest to draw on the region's genetic diversity and deep expertise in the hope of benefiting people everywhere. But the $46 million from the US for the project was disappearing, part of the dismantling of foreign aid by the world's biggest donor earlier this year as President Donald Trump announced a focus on priorities at home. South Africa hit hard by aid cuts South Africa has been hit especially hard because of Trump's baseless claims about the targeting of the ..